Demand for obesity drugs shoots up in India as Lilly, Novo jostle for market share

India's obesity drug market is experiencing rapid growth, quintupling since 2021 to 6.28 billion rupees, fueled by rising obesity rates and consumer adoption. Eli Lilly's Mounjaro saw sales double between May and June to 260 million rupees, while Novo Nordisk's Wegovy, though newly launched, benefits from semaglutide's two-thirds market dominance. This burgeoning market is poised for significant competitive shifts, particularly with semaglutide's patent expiry in India in 2026, which is expected to attract generic drugmakers and solidify India as a critical strategic battleground for global pharmaceutical companies in the obesity sector.

Analysis

The Indian obesity drug market is experiencing explosive growth, having expanded fivefold since 2021 to a current valuation of 6.28 billion rupees, propelled by high disease incidence and strong consumer adoption. This has established a key competitive arena for Eli Lilly (LLY) and Novo Nordisk (NVO). Eli Lilly's Mounjaro (tirzepatide) has shown remarkable initial momentum since its late March launch, with sales doubling from May to June to reach 87,986 units, or 260 million rupees ($3.03 million). This rapid uptake has allowed tirzepatide to capture an 8% market share. Meanwhile, Novo Nordisk leverages its incumbent position with semaglutide, which commands a dominant two-thirds of the Indian market, valued at 4.12 billion rupees. Although its newly launched Wegovy has sold a modest 1,788 units, Novo has been selling oral semaglutide in the country since 2022. The competitive landscape is set for a significant disruption with the upcoming patent expiration for semaglutide in 2026, which is expected to usher in generic competition and intensify the battle for market share.

Key Decisions for Investors

• Investors should view Eli Lilly's strong Mounjaro launch, with sales doubling in a single month, as a significant positive indicator of its ability to penetrate a high-growth emerging market, and should monitor subsequent sales data to assess if this early momentum is sustained.
• For Novo Nordisk, while its semaglutide franchise currently dominates with a two-thirds market share, the looming 2026 patent expiration in India poses a material risk from generic competition, warranting close attention to its strategy for defending market share and pricing power.
• The overall market's rapid expansion makes the Indian obesity drug segment a critical area to watch, with the primary dynamic being the near-term brand-versus-brand competition between Lilly and Novo, followed by a long-term shift towards brand-versus-generic dynamics post-2026.